J. Stuart Ferriss - Concepedia

Author

J. Stuart Ferriss

Also Known As

J Stuart Ferriss, J. Ferriss, J. S. Ferriss, J. Stuart Ferriss, J.S. Ferriss, JStuart Ferriss, James Ferriss, James S. Ferriss, James Stuart Ferriss, Stuart J. Ferriss

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of Virginia Temple University University of Virginia Health System Johns Hopkins Medicine Johns Hopkins University

About

J. Stuart Ferriss is an author at University of Virginia specializing in medicine, obstetrics, and gynecology oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	707
2	Health Sciences	3	3	178
3	Public Health	1	1	41
4	Social Sciences	1	1	41
5	African American Studies	1	1	41

J. Stuart Ferriss

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Journal of Clinical Oncology	2019	461
When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes Linda Duska, Leslie A. Garrett, Melissa Henretta, Gynecologic Oncology Thrombosis‘ Never-eventsVenous DiseaseTumoral PathologyVenous Thrombosis	2009	129
Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance J. Stuart Ferriss, Youngchul Kim, Linda Duska, PLoS ONE Adjuvant ChemotherapyGynecologyPathologyCancer BiologyTumor Biology	2012	115
Cancer in Obese Women: Potential Protective Impact of Bariatric Surgery Gwyneth M. McCawley, J. Stuart Ferriss, Dyanna L. Geffel, Journal of the American College of Surgeons	2009	94
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study Britt Erickson, Omar Najjar, Shari Damast, Gynecologic Oncology Multi-institutional Cohort StudyTumoral PathologyMedicineGynecologyPathology	2020	83
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study J. Stuart Ferriss, James Java, Michael A. Bookman, Gynecologic Oncology Front-line TherapyMedicineCancer ManagementPathologyGynecology	2015	82
Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma Amir A. Jazaeri, Jennifer Bryant, Hong Park, Neoplasia	2011	70
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates Stefany Acosta‐Torres, Tricia Murdock, Rayna K. Matsuno, Gynecologic Oncology InfertilityUrologyFertility-sparing TreatmentFertilityLow Live-birth Rates	2020	41
Are ethnic and racial minority women less likely to participate in clinical trials? Shweta N. Patel, Jeanine N. Staples, Christine Garcia, Gynecologic Oncology Racial Minority WomenMedicineGender StudiesClinical PopulationBlack Women	2020	41

Page 1